We revealed that blockade of the NF-κB pathway by Bortezomib, a 20S proteasome inhibitor and FDA-approved drug for multiple myeloma and mantle cell lymphoma10, could render CRC more sensitive to BETi, through synergistic repression of c-myc and FOXM1. Here, FOXM1 is linked to colorectal carcinoma.